ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

Results from the RELATIVITY-047 study on the multiple myeloma landscape are evaluated by Dr Evan Lipson.

Video content above is prompted by the following:

  • Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs nivolumab in patients with previously untreated metastatic or unresectable melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study.
    • How might these findings impact the management of patients with metastatic melanoma?
  • The study examined melanoma-specific survival (MSS) outcomes. What is the significance of sustained improvement in MSS observed with nivolumab plus relatlimab?
Related Videos
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Alfred L. Garfall, MD, an expert on multiple myeloma
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
CH LogoCenter for Biosimilars Logo